Cargando…

Engagement with tNOX (ENOX2) to Inhibit SIRT1 and Activate p53-Dependent and -Independent Apoptotic Pathways by Novel 4,11-Diaminoanthra[2,3-b]furan-5,10-diones in Hepatocellular Carcinoma Cells

Hepatocellular carcinoma (HCC) is the most frequent primary malignancy of the liver and is among the top three causes of cancer-associated death worldwide. However, the clinical use of chemotherapy for HCC has been limited by various challenges, emphasizing the urgent need for novel agents with impr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chia-Yang, Islam, Atikul, Su, Claire J., Tikhomirov, Alexander S., Shchekotikhin, Andrey E., Chuang, Show-Mei, Chueh, Pin Ju, Chen, Yao Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468551/
https://www.ncbi.nlm.nih.gov/pubmed/30909652
http://dx.doi.org/10.3390/cancers11030420
_version_ 1783411459643932672
author Lin, Chia-Yang
Islam, Atikul
Su, Claire J.
Tikhomirov, Alexander S.
Shchekotikhin, Andrey E.
Chuang, Show-Mei
Chueh, Pin Ju
Chen, Yao Li
author_facet Lin, Chia-Yang
Islam, Atikul
Su, Claire J.
Tikhomirov, Alexander S.
Shchekotikhin, Andrey E.
Chuang, Show-Mei
Chueh, Pin Ju
Chen, Yao Li
author_sort Lin, Chia-Yang
collection PubMed
description Hepatocellular carcinoma (HCC) is the most frequent primary malignancy of the liver and is among the top three causes of cancer-associated death worldwide. However, the clinical use of chemotherapy for HCC has been limited by various challenges, emphasizing the urgent need for novel agents with improved anticancer properties. We recently synthesized and characterized a series of 4,11-diaminoanthra[2,3-b]furan-5,10-dione derivatives that exhibit potent apoptotic activity against an array of cancer cell lines, including variants with multidrug resistance. Their effect on liver cancer cells, however, was unknown. Here, we investigated three selected 4,11-diaminoanthra[2,3-b]furan-5,10-dione derivatives (compounds 1–3) for their cytotoxicity and the underlying molecular mechanisms in wild-type or p53-deficient HCC cells. Cytotoxicity was determined by WST-1 assays and cell impedance measurements and apoptosis was analyzed by flow cytometry. The interaction between compounds and tumor-associated NADH oxidase (tNOX, ENOX2) was studied by cellular thermal shift assay (CETSA). We found that compound 1 and 2 induced significant cytotoxicity in both HepG2 and Hep3B lines. CETSA revealed that compounds 1 and 2 directly engaged with tNOX, leading to a decrease in the cellular NAD(+)/NADH ratio. This decreased the NAD(+)-dependent activity of Sirtuin 1 (SIRT1) deacetylase. In p53-wild-type HepG2 cells, p53 acetylation/activation was enhanced, possibly due to the reduction in SIRT1 activity, and apoptosis was observed. In p53-deficient Hep3B cells, the reduction in SIRT1 activity increased the acetylation of c-Myc, thereby reactivating the TRAIL pathway and, ultimately leading to apoptosis. These compounds thus trigger apoptosis in both cell types, but via different pathways. Taken together, our data show that derivatives 1 and 2 of 4,11-diaminoanthra[2,3-b]furan-5,10-diones engage with tNOX and inhibit its oxidase activity. This results in cytotoxicity via apoptosis through tNOX-SIRT1 axis to enhance the acetylation of p53 or c-Myc in HCC cells, depending on their p53 status.
format Online
Article
Text
id pubmed-6468551
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64685512019-04-24 Engagement with tNOX (ENOX2) to Inhibit SIRT1 and Activate p53-Dependent and -Independent Apoptotic Pathways by Novel 4,11-Diaminoanthra[2,3-b]furan-5,10-diones in Hepatocellular Carcinoma Cells Lin, Chia-Yang Islam, Atikul Su, Claire J. Tikhomirov, Alexander S. Shchekotikhin, Andrey E. Chuang, Show-Mei Chueh, Pin Ju Chen, Yao Li Cancers (Basel) Article Hepatocellular carcinoma (HCC) is the most frequent primary malignancy of the liver and is among the top three causes of cancer-associated death worldwide. However, the clinical use of chemotherapy for HCC has been limited by various challenges, emphasizing the urgent need for novel agents with improved anticancer properties. We recently synthesized and characterized a series of 4,11-diaminoanthra[2,3-b]furan-5,10-dione derivatives that exhibit potent apoptotic activity against an array of cancer cell lines, including variants with multidrug resistance. Their effect on liver cancer cells, however, was unknown. Here, we investigated three selected 4,11-diaminoanthra[2,3-b]furan-5,10-dione derivatives (compounds 1–3) for their cytotoxicity and the underlying molecular mechanisms in wild-type or p53-deficient HCC cells. Cytotoxicity was determined by WST-1 assays and cell impedance measurements and apoptosis was analyzed by flow cytometry. The interaction between compounds and tumor-associated NADH oxidase (tNOX, ENOX2) was studied by cellular thermal shift assay (CETSA). We found that compound 1 and 2 induced significant cytotoxicity in both HepG2 and Hep3B lines. CETSA revealed that compounds 1 and 2 directly engaged with tNOX, leading to a decrease in the cellular NAD(+)/NADH ratio. This decreased the NAD(+)-dependent activity of Sirtuin 1 (SIRT1) deacetylase. In p53-wild-type HepG2 cells, p53 acetylation/activation was enhanced, possibly due to the reduction in SIRT1 activity, and apoptosis was observed. In p53-deficient Hep3B cells, the reduction in SIRT1 activity increased the acetylation of c-Myc, thereby reactivating the TRAIL pathway and, ultimately leading to apoptosis. These compounds thus trigger apoptosis in both cell types, but via different pathways. Taken together, our data show that derivatives 1 and 2 of 4,11-diaminoanthra[2,3-b]furan-5,10-diones engage with tNOX and inhibit its oxidase activity. This results in cytotoxicity via apoptosis through tNOX-SIRT1 axis to enhance the acetylation of p53 or c-Myc in HCC cells, depending on their p53 status. MDPI 2019-03-24 /pmc/articles/PMC6468551/ /pubmed/30909652 http://dx.doi.org/10.3390/cancers11030420 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lin, Chia-Yang
Islam, Atikul
Su, Claire J.
Tikhomirov, Alexander S.
Shchekotikhin, Andrey E.
Chuang, Show-Mei
Chueh, Pin Ju
Chen, Yao Li
Engagement with tNOX (ENOX2) to Inhibit SIRT1 and Activate p53-Dependent and -Independent Apoptotic Pathways by Novel 4,11-Diaminoanthra[2,3-b]furan-5,10-diones in Hepatocellular Carcinoma Cells
title Engagement with tNOX (ENOX2) to Inhibit SIRT1 and Activate p53-Dependent and -Independent Apoptotic Pathways by Novel 4,11-Diaminoanthra[2,3-b]furan-5,10-diones in Hepatocellular Carcinoma Cells
title_full Engagement with tNOX (ENOX2) to Inhibit SIRT1 and Activate p53-Dependent and -Independent Apoptotic Pathways by Novel 4,11-Diaminoanthra[2,3-b]furan-5,10-diones in Hepatocellular Carcinoma Cells
title_fullStr Engagement with tNOX (ENOX2) to Inhibit SIRT1 and Activate p53-Dependent and -Independent Apoptotic Pathways by Novel 4,11-Diaminoanthra[2,3-b]furan-5,10-diones in Hepatocellular Carcinoma Cells
title_full_unstemmed Engagement with tNOX (ENOX2) to Inhibit SIRT1 and Activate p53-Dependent and -Independent Apoptotic Pathways by Novel 4,11-Diaminoanthra[2,3-b]furan-5,10-diones in Hepatocellular Carcinoma Cells
title_short Engagement with tNOX (ENOX2) to Inhibit SIRT1 and Activate p53-Dependent and -Independent Apoptotic Pathways by Novel 4,11-Diaminoanthra[2,3-b]furan-5,10-diones in Hepatocellular Carcinoma Cells
title_sort engagement with tnox (enox2) to inhibit sirt1 and activate p53-dependent and -independent apoptotic pathways by novel 4,11-diaminoanthra[2,3-b]furan-5,10-diones in hepatocellular carcinoma cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468551/
https://www.ncbi.nlm.nih.gov/pubmed/30909652
http://dx.doi.org/10.3390/cancers11030420
work_keys_str_mv AT linchiayang engagementwithtnoxenox2toinhibitsirt1andactivatep53dependentandindependentapoptoticpathwaysbynovel411diaminoanthra23bfuran510dionesinhepatocellularcarcinomacells
AT islamatikul engagementwithtnoxenox2toinhibitsirt1andactivatep53dependentandindependentapoptoticpathwaysbynovel411diaminoanthra23bfuran510dionesinhepatocellularcarcinomacells
AT suclairej engagementwithtnoxenox2toinhibitsirt1andactivatep53dependentandindependentapoptoticpathwaysbynovel411diaminoanthra23bfuran510dionesinhepatocellularcarcinomacells
AT tikhomirovalexanders engagementwithtnoxenox2toinhibitsirt1andactivatep53dependentandindependentapoptoticpathwaysbynovel411diaminoanthra23bfuran510dionesinhepatocellularcarcinomacells
AT shchekotikhinandreye engagementwithtnoxenox2toinhibitsirt1andactivatep53dependentandindependentapoptoticpathwaysbynovel411diaminoanthra23bfuran510dionesinhepatocellularcarcinomacells
AT chuangshowmei engagementwithtnoxenox2toinhibitsirt1andactivatep53dependentandindependentapoptoticpathwaysbynovel411diaminoanthra23bfuran510dionesinhepatocellularcarcinomacells
AT chuehpinju engagementwithtnoxenox2toinhibitsirt1andactivatep53dependentandindependentapoptoticpathwaysbynovel411diaminoanthra23bfuran510dionesinhepatocellularcarcinomacells
AT chenyaoli engagementwithtnoxenox2toinhibitsirt1andactivatep53dependentandindependentapoptoticpathwaysbynovel411diaminoanthra23bfuran510dionesinhepatocellularcarcinomacells